Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile ‌obesity drug from its recent $10 billion Metsera purchase that raises ‌questions about its tolerability for patients, and ...
Pfizer targets 2028 for its first obesity drug approval Company plans to advance more than 20 obesity trials in 2026 RSV vaccine quarterly sales top expectations Feb 3 (Reuters) - Pfizer (PFE.N), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results